Novartis's COPD drug indacaterol better than Spiriva in Phase III
This article was originally published in Scrip
Executive Summary
Novartis's investigational bronchodilator, indacaterol (QAB149), has demonstrated a greater improvement in lung function than that of the bestselling treatment, Boehringer Ingelheim/Pfizer's Spiriva (tiotropium), in patients with chronic obstructive pulmonary disease (COPD) in a Phase III trial.